Advertisement · 728 × 90
#
Hashtag
#Gyre
Advertisement · 728 × 90
Preview
Scientists finally develop a plan to clean up the massive North Pacific Garbage Patch A new plan aims to clean more than 80% of the North Pacific Garbage Patch - the ocean's largest floating plastic garbage patch.

“Inside that retention zone…plastic slows down while water keeps moving past. Because the system moves slowly, animals have more time to avoid it, and crews can open escape routes when needed.“

All good, but we have to stop putting more plastic there. #gyre #FossilFuels

0 0 0 0
Preview
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment Gyre Therapeutics (Nasdaq: GYRE) announced that China’s NMPA Center for Drug Evaluation granted priority review to the NDA for Hydronidone (F351) to treat CHB‑induced liver fibrosis on March 17, 2026. The CDE decision follows a pre‑NDA communication meeting on January 5, 2026.Gyre plans to submit a formal NDA in the near future through its majority‑owned subsidiary, Gyre Pharmaceuticals Co., Ltd., and will work with CDE during the review.

#GYRE Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

www.stocktitan.net/news/GYRE/gyre-therapeut...

0 0 0 0
Preview
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline; transaction anticipated to close in

#GYRE Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/GYRE/gyre-therapeut...

1 0 0 0
Post image Post image Post image Post image

I REQUIRE more Gyre x Voruna holy shit, Inject these two into my veins or something 😭❤️

Voruna and Gyre by/from the tools from the warframe archive discord

#r34 #nsfw #nsfwart #3dporn #blender #blender3d #warframe #gyre #voruna

6 1 0 0
Post image

~ Dance Into Eternity ~
#Gyre

cc @warframe.com

#captura #warframe #warframecaptura #WarframeCreator #tenno #gamingphotography #VPRT #VirtualPhotography #PhotoMode #videogame

4 1 0 0
Post image Post image

Oh and can't forget the lewd version ofc :3

Separate post in case some peeps don't want to see warframe porn lmao

Voruna and Gyre by/from the tools from the warframe archive discord

#r34 #nsfw #nsfwart #3dporn #blender #blender3d #warframe #gyre #voruna

4 0 0 0
Post image

As a wise Cetus shrine maiden once said: "I'd fight fate itself just so i can see your beauty one more time"

Wanted to pair up my favorite warframes together <3

#blender #blender3d #warframe #gyre #voruna

4 0 1 0

Ninety percent of the garbage washed ashore now are plastics. Numerous groups visit the beach to clean it up, but even with these efforts the beach continually receives more trash. #Hawaii #Gyre #Plastics

0 0 0 0
Preview
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting Gyre Therapeutics (Nasdaq: GYRE) completed a Pre-NDA meeting with China’s CDE that agreed existing Phase 3 data for Hydronidone generally support a conditional approval NDA and indicated priority review eligibility, subject to formal filing and review. The Phase 3 topline showed 52.85% of treated patients achieved ≥1-stage fibrosis regression at Week 52 vs 29.84% for placebo (p=0.0002).The company expects to submit an NDA for conditional approval in the first half of 2026 and will run a confirmatory Phase 3c trial in China to evaluate liver-related clinical outcomes needed to convert conditional approval to regular approval. Hydronidone previously received Breakthrough Therapy designation from the NMPA (March 2021).

#GYRE Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

www.stocktitan.net/news/GYRE/gyre-therapeut...

0 0 0 0
Post image Post image Post image

Life is beautiful : 衣・食植・住 “植物が命をまもる衣や家となり、命をつなぐ食となる” by eatrip(GYRE GALLERY・表参道) #gyre #gyregallery #ジャイル #ジャイルギャラリー

0 0 0 0
Post image Post image Post image

Life is beautiful : 衣・食植・住 “植物が命をまもる衣や家となり、命をつなぐ食となる” by eatrip(GYRE GALLERY・表参道) #gyre #gyregallery #ジャイル #ジャイルギャラリー

0 0 1 0
Post image Post image Post image

Life is beautiful : 衣・食植・住 “植物が命をまもる衣や家となり、命をつなぐ食となる” by eatrip(GYRE GALLERY・表参道) #gyre #gyregallery #ジャイル #ジャイルギャラリー

1 0 1 0
Post image

💜_💜 #gyre #warframe #warframecaptura

3 0 0 0
Post image

Voltaic Lich

#Warframe #WarframeCaptura #FashionFrame #Gyre

18 2 1 0
Post image

Electric Vanity

#Warframe #WarframeCaptura #FashionFrame #Gyre

22 2 1 0
Post image

Gyre Prime!

Filling the trenches with electricity

I post Mon Wed Fri weekly!

#warframe #warframefanart #tennocreate #art #digitalart #huion #dailyart #drawing #fanart #lady #scifi #ninja #Warframe1999 #gaming #gyre #prime #grineer #warframetheoldpeace

6 2 0 0
Post image

你好,我們將在12/10(三)午夜更新後開始我老婆的地獄馬拉松活動
-Gyre Prime 五套
-交電步槍 Prime 五套
-紅隼 Prime 五套
總計五組的我婆實況馬拉松 將於實況結束前抽出一名幸運觀眾,一組本次更新P版武器跟戰甲。
-
🦌我的實況📺 : twitch.tv/hideyak_ow

#Hideyak #Warframe #Gyre

0 0 0 0
Post image

Gyre on the Zariman
#gyre #warframe #tenno #digitalextremes #DE

50 22 0 0
Preview
M42T - Twitch 🔴[FR/EN]On se prépare pour Gyre prime dans moins d'un mois ! !fr !rs #tennocreate

Booonsoir les Tennos on part sur #Warframe ! Ce soir on se prépare pour l'arrivée de #Gyre Prime d'ici moins d'un mois ! Let's gooooooooo : www.twitch.tv/m42t
#Tennocreate

1 0 0 0

Am I the only one whobthinks she needs a small rework? It needs Cathode Current to be inherent on the 3rd and 4th at least to be decently functional, or have a smaller cooldown on the 3rd cmoooooon

#warframe #gyre

1 0 0 0
Preview
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update Gyre Therapeutics (Nasdaq: GYRE) reported Q3 2025 results and a business update on Nov 7, 2025. Q3 revenue was $30.6M (+20% YoY) and GAAP net income was $5.9M. Nine-month revenue totaled $79.4M and cash and deposits were $80.3M as of Sept 30, 2025 (up 57% YTD). The company revised full-year 2025 revenue guidance to $115–118M (down from $118–128M) citing delayed Etorel rollout and government procurement uncertainty. Commercial sales in Q3 included ETUARY $27.7M, Etorel $1.5M, and Contiva $1.2M. Pipeline: Hydronidone NDA interactions in China progressing with Priority Review discussions; U.S. IND timing moved to 2026. Pirfenidone Phase 3 pneumoconiosis enrollment completed (272 patients).

#GYRE Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

www.stocktitan.net/news/GYRE/gyre-therapeut...

0 0 0 0
Trade Alerts, Thursday November 6, 2025 – Crystal Equity Research

Small-cap stocks in new ADX downtrend, Thu Nov 6th - #FTFT #GYRE #HTLD #DMLP #CVAC #INGN #JSPR #BHST #KPRX #MXCT #AIOT #WDH #SITC #NPB #NOTE #MED #JBI #DEA #CNMD #BLND #SGN #KAPA #UAVS #VVPR #TRNS #RPD #PSEC - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

"Impacts of subpolar #gyre tipping may not be as severe as those of a full #AMOC collapse, but fast timescale & possibility of it happening in near future are worrying. The risk is real, with most realistic models all showing a collapse, & the impacts on 🇪🇺 will be substantial."
- @swinda.bsky.social

4 2 1 0
Preview
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis Gyre Therapeutics (NASDAQ: GYRE) announced completion of patient enrollment in its 52-week Phase 3 trial of Pirfenidone capsules for pneumoconiosis on Oct 15, 2025. The randomized, double-blind, placebo-controlled study enrolled 272 patients across 18 centers in China to evaluate 52 weeks of treatment for progressive pulmonary fibrosis caused by mineral dust exposure. The company noted a significant unmet medical need: no approved therapies in China specifically target fibrotic mechanisms in pneumoconiosis, which affects >450,000 surviving patients in China. The trial completion of enrollment is a key operational milestone ahead of safety and efficacy readouts.

#GYRE Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

www.stocktitan.net/news/GYRE/gyre-therapeut...

0 0 0 0
Preview
“The Ocean’s Heartbeat Is Faltering”: This North Atlantic Shift Could Trigger Violent Weather and Upend Global Climate (and It’s Already Starting) The behavior of the North Atlantic subpolar gyre, a crucial ocean current system, has recently sparked concern among scientists. Recent studies have shown

“The Ocean’s Heartbeat Is Faltering”: This North Atlantic Shift Could Trigger Violent Weather and Upend Global Climate (and It’s Already Starting) www.sustainability-times.com/climate/the-... #ClimateCrisis #FossilFuels #SevereWeather #Ocean #Currents #Gyre #NorthAtlantic

6 1 1 2
Post image

My pretty Gyre 💗
#Warframe #Gyre

7 1 0 0

William Butler #Yeats' poem the #Second #Coming just rhymes with how the world feels right now:

Turning and turning in the widening #gyre
The falcon cannot hear the #falconer;
Things fall apart; the centre cannot hold;
Mere #anarchy is loosed upon the world,

0 0 1 0
Preview
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update Gyre Therapeutics (NASDAQ:GYRE) reported Q2 2025 financial results with revenue of $26.8 million and net income of $1.6 million. The company announced a leadership change as Ping Zhang, Executive Chairman, was appointed interim CEO while Dr. Han Ying transitions to SVP of Science.Key highlights include positive Phase 3 results for Hydronidone in CHB-associated liver fibrosis, successful launch of Etorel for SSc-ILD and PF-ILD treatments, and NMPA approval for pirfenidone clinical trials. The company reaffirmed its full-year 2025 revenue guidance of $118-128 million.Financial position remains strong with $75.9 million in total cash and investments, bolstered by a $23 million public offering completed in May 2025.

#GYRE Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

www.stocktitan.net/news/GYRE/gyre-therapeut...

0 0 0 0